FDA again delays Portola's BLA for bleeding antidote to Eliquis, Xarelto
admin 28th December 2017 Uncategorised 0Pfizer and Bristol-Myers Squibb, as well as Bayer and Johnson & Johnson were hoping to hear that a bleeding antidote for their blood thinners Eliquis and Xarelto would be approved early next year. Instead they will have to wait at least until spring after the FDA again delayed consideration of AndexXa, a universal bleeding reversal agent being developed by Portola Pharmaceuticals.
More: FDA again delays Portola's BLA for bleeding antidote to Eliquis, Xarelto
Source: fierce